Arrhythmogenic right ventricular cardiomyopathy/dys-plasia (ARVC/D) is an important cause of ventricular tachyarrhythmias and sudden death in young patients and athletes with apparently normal hearts. The disease is characterized by localized or diffuse atrophy of predominantly right ventricular myocardium with subsequent replacement by fatty and fibrous tissue. As a result of these pathomorphological alterations, global and regional right (and left) ventricular dysfunction and ventricular tachyarrhythmias due to areas of slow conduction and dispersion of refractoriness are the major clinical findings and manifestations of ARVC/D [1-4].
The need for antiarrhythmic therapy in ARVC/D has been advocated to improve symptoms and prognosis. Because the prognosis of ARVC/D is largely determined by ventricular tachyarrhythmias, risk stratification is required for management decisions and prevention of sudden cardiac death.
Was this article helpful?